NIH Study Finds Lower Concentration of PrEP Drug in Pregnant Young Women | HIV.gov

NIH Study Finds Lower Concentration of PrEP Drug in Pregnant Young Women | HIV.gov

Drug-Delivery Technology Leads to Sustained HIV Antibody Production in NIH Study A new approach to direct the body to make a specific antibody against HIV led to sustained production of that antibody for more than a year among participants in a National Institutes of Health clinical trial. LEARN MORE

NIH Study Finds Lower Concentration of PrEP Drug in Pregnant Young Women  Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth. LEARN MORE   HIV.gov's CROI Coverage In case you missed last week's update, the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from March 8-11 has become a virtual conference in response to concerns related to the new coronavirus. We’ll continue to share research highlights from our federal partners through our blog, emails, and across our social media accounts. And stay tuned for a revised schedule of video interviews about research presented at CROI.   Scientific advances in HIV prevention, care, and treatment have put the goals of Ending the HIV Epidemic: A Plan for America within reach.